This grant is for developing combined neuromodulation and behavioral treatment algorithms, addressing the critical absence of FDA-approved interventions for Stimulant Use Disorder (StUD). It specifically targets vulnerable phenotypes characterized by cognitive dysfunction, impulsivity, and executive function deficits. Leveraging proven neuromodulation techniques alongside behavioral therapies like CBT and mindfulness, this initiative aims to provide a much-needed treatment option. The goal is to create efficacious interventions that reduce stimulant use and prevent relapse, overcoming barriers posed by StUD’s heterogeneity. Rigorous randomized controlled trials are required to establish and optimize these therapeutic algorithms.
Opportunity ID: 355169
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-DA-25-057 |
| Funding Opportunity Title: | Combined Neuromodulation and Behavioral Treatment Algorithm Development for Stimulant Use Disorder (StUD) Enriched for Vulnerable Phenotype (U01 Clinical Trial Required) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Education Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.279 — Drug Abuse and Addiction Research Programs |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Jun 27, 2024 |
| Last Updated Date: | Jun 27, 2024 |
| Original Closing Date for Applications: | Nov 27, 2024 |
| Current Closing Date for Applications: | Nov 27, 2024 |
| Archive Date: | Jan 02, 2025 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | $500,000 |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Independent school districts State governments Public and State controlled institutions of higher education Private institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Special district governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education For profit organizations other than small businesses Public housing authorities/Indian housing authorities Others (see text field entitled “Additional Information on Eligibility” for clarification) Native American tribal governments (Federally recognized) County governments Small businesses City or township governments Native American tribal organizations (other than Federally recognized tribal governments) |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | Stimulant Use Disorder still does not have FDA- approved treatments. Neuromodulation, such as, for example, transcranial magnetic stimulation (TMC) has been successfully used for more than 10 years in major depressive disorder (MDD) where patients have failed one antidepressant and since 2018 it has been used for obsessive-compulsive disorder (OCD). Another example is transcranial direct current stimulation (tDCS) which is currently being developed for a range of mental and neurological conditions, and some of them have direct relevance for StUD vulnerable phenotype (cognitive dysfunction, compulsive, and impulsive traits). Other neuromodulation technologies potentially can also be applied to StUD. As not everyone who takes drugs becomes addicted, and while the StUD population’s extreme heterogeneity represents a barrier to effective treatment development, there is a treatment gap that needs to be filled, especially for the high-risk vulnerable phenotype with low executive function and difficulties with response regulation – anxious-impulsive traits. Developing neuromodulation combined with behavioral treatment modalities (CBT, mindfulness-based approaches) that will help to maintain use decrease and prevent relapse would have tremendous value as a treatment option. Randomized controlled trials are needed to develop the treatment algorithms and to select the most efficacious one. |
| Link to Additional Information: | https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-057.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH Grants Information
grantsinfo@nih.gov Email:grantsinfo@nih.gov |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
Folder 355169 Full Announcement-RFA-DA-25-057 -> RFA-DA-25-057-Full-Announcement.pdf
Packages
| Agency Contact Information: | NIH Grants Information grantsinfo@nih.gov Email: grantsinfo@nih.gov |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-H | Use for due dates on or before January 24, 2025 | PKG00287209 | Oct 27, 2024 | Jan 24, 2025 | View |
Package 1
Mandatory forms
355169 RR_SF424_5_0-5.0.pdf
355169 PHS398_CoverPageSupplement_5_0-5.0.pdf
355169 RR_OtherProjectInfo_1_4-1.4.pdf
355169 PerformanceSite_4_0-4.0.pdf
355169 RR_KeyPersonExpanded_4_0-4.0.pdf
355169 PHS398_ResearchPlan_5_0-5.0.pdf
355169 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
355169 RR_Budget_3_0-3.0.pdf
355169 RR_SubawardBudget30_3_0-3.0.pdf
355169 PHS398_ModularBudget_1_2-1.2.pdf
355169 PHS_AssignmentRequestForm_3_0-3.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
